Alex Beacom
YOU?
Author Swipe
View article: A Multi-Modal Analysis of Acquired Resistance to Acalabrutinib and Pirtobrutinib Provides Potential Strategies to Augment Treatment Outcome with BTKi Drugs
A Multi-Modal Analysis of Acquired Resistance to Acalabrutinib and Pirtobrutinib Provides Potential Strategies to Augment Treatment Outcome with BTKi Drugs Open
Introduction: Acalabrutinib (acala), a covalent BTK inhibitor (BTKi), exhibits excellent efficacy and safety in CLL and other B cell malignancies. However, long term efficacy is often compromised by the acquisition of mutations at the acal…